Lilly dips as biomed chief Christi Shaw heads to GileadChristi Shaw, president of Eli Lilly Bio-Medicines is leaving the company after two years, taking the top job Share XLilly dips as biomed chief Christi Shaw heads to Gileadhttps://pharmaphorum.com/news/lilly-dips-as-biomed-chief-christi-shaw-heads-to-gilead/
FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failureEli Lilly and Boehringer Ingelheim’s Jardiance was the first diabetes drug to lower the risk of cardiovascular disease Share XFDA fast-tracks Lilly/Boehringer’s Jardiance for heart failurehttps://pharmaphorum.com/news/fda-fast-tracks-lilly-boehringers-jardiance-for-heart-failure/
Three drugmakers challenge Trump’s price disclosure rulingAmgen, Merck & Co and Eli Lilly have launched a legal challenge to a new rule that will Share XThree drugmakers challenge Trump’s price disclosure rulinghttps://pharmaphorum.com/news/three-drugmakers-challenge-trumps-price-disclosure-ruling/
Sanofi, Lilly and Novo make cases for diabetes drugs at ADAThe American Diabetes Association (ADA) annual conference has dominated the medical research headlines this weekend as pharma and Share XSanofi, Lilly and Novo make cases for diabetes drugs at ADAhttps://pharmaphorum.com/news/sanofi-lilly-and-novo-diabetes/
Lilly moves Crohn’s drug into phase 3, faces safety setback in JapanEli Lilly has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab, Share XLilly moves Crohn’s drug into phase 3, faces safety setback in Japanhttps://pharmaphorum.com/news/lilly-moves-crohns-drug-mirikizumab/
Oncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and moreAZ and Daiichi Sankyo announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan, Share XOncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and morehttps://pharmaphorum.com/views-and-analysis/oncology-round-up-az-and-daiichi-score-key-trial-win-with-breast-cancer-antibody-and-more/
SMC approves medicines for breast cancer, skin cancer, schizophreniaThe Scottish Medicines Consortium (SMC) has given approvals to Lilly’s breast cancer drug Verzenios, Merck’s Keytruda and Allergan’s Share XSMC approves medicines for breast cancer, skin cancer, schizophreniahttps://pharmaphorum.com/news/smc-approves-medicines-for-breast-cancer-skin-cancer-schizophrenia/
Lilly gets fifth use for Cyramza with FDA liver cancer nodEli Lilly’s Cyramza has a new string to its bow after the FDA approved it as a second-line Share XLilly gets fifth use for Cyramza with FDA liver cancer nodhttps://pharmaphorum.com/news/lilly-gets-fifth-use-for-cyramza-with-fda-liver-cancer-nod/
Pfizer/Lilly non-opioid pain drug shows more positive resultsResults from a new study of Pfizer and Lilly’s non-opioid pain drug tanezumab have shown that it can Share XPfizer/Lilly non-opioid pain drug shows more positive resultshttps://pharmaphorum.com/news/pfizer-lilly-non-opioid-pain-drug-shows-more-positive-results/
